Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Bortezomib 9Cyclophosphamide 7tanespimycin 4fludarabine phosphate 4Vorinostat 4Paclitaxel 4Filgrastim 4Carboplatin 4fludarabine 3Peripheral Blood Stem Cell Transplantation 3Lenalidomide 3Irinotecan 3Everolimus 3Etoposide 3Doxorubicin 3Dasatinib 3Azacitidine 3sargramostim 2romidepsin 2laromustine 2ixabepilone 2entinostat 2belinostat 2Whole-Body Irradiation 2Vincristine 2Topotecan 2Tacrolimus 2Radiotherapy 2Prednisone 2Pharmacogenomic Testing 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Immunoblastic Lymphadenopathy × visilizumab × Clear all
NCT00006009 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡